Oncology: Bridging Clinical Trials and Patient Care
AHMEDABAD, India, February 24, 2014 /PRNewswire/ --
As a part of its corporate social responsibility initiative, Lambda had organized a symposium dedicated to oncology titled 'Oncology - New Horizons'. It was an event built around knowledge sharing and understanding the latest advances and newer modalities of treatments amidst some of the leading cancer treatment centers and top oncologists/clinicians across the world.
Oncology was the focus point of the symposium as it is one of the leading maladies across the world and in India in particular. Its occurrence is growing year on year globally and, hence there is a dire need to have a focussed approach in treatment modalities and continuous research to make therapy affordable, especially in developing countries like India. Latest advances from a global perspective like novel immunotherapies, newer Biomarkers for early detection, screening modalities and more were discussed, which were of immense benefit to practising oncologists in India for betterment of their patients' lives.
Envisioned by their Managing Director - Mrs. Bindi Chudgar, the two-day long symposium, scheduled on 21st and 22nd February 2014 and hosted at Lambda's state-of-the-art facilities in Ahmedabad, had a strong international participation from guest speakers from USA and UK, eminent oncologists from well-known centers across India, and of course senior scientists from the Indian pharmaceutical industry. Inaugurated by Mr. D G Shah - Secretary General, IPA and Dr Pankaj Shah, well-known hematologist and ex-director GCRI, there was a valuable sharing experience.
Among the many distinguished speakers were Padmashri Dr. Ashok Vaid, Chairman Oncology from Medanta Cancer Institute who spoke on 'Management approach in Lung Cancer', Dr. Mahesh Desai, Medical Director from MPUH, Nadiad who elaborated on 'Partial Nephrectomy in Kidney Tumours', Dr. Vamsidhar Velcheti from Cleaveland Clinic, US and Dr. Karthik Ramasamy from Oxford University, UK who gave a different and additional view of their experiences in the US and UK in treating the most difficult malady of the world.
It was a hugely successful event and was well appreciated by the oncology fraternity from across the globe, setting benchmarks in the CRO industry.
Lambda Therapeutic Research, under the strong and able leadership of Mrs. Bindi Chudgar, their Managing Director, today has emerged as a global multinational CRO, offering varied services spread across the clinical research spectrum like BA/BE studies, multi-therapeutic clinical trials including oncology, medical imaging, and pharmacovigilance. As India's largest CRO, Lambda has spread its operations and built world class, state-of-the-art infrastructure in North America, the United Kingdom, Europe, South East Asia and India.
For more information please visit: www.lambda-cro.com
Primary Media Contact: Pritesh Trivedi, [email protected], 91-97272-60309
Secondary Media Contact: Gaurang Darji, [email protected], 91-99250-38960
Share this article